Author: Ravi Shankar

Increases full year DEPS guidance

SARASOTA, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) reported financial results for the third quarter ended September 30, 2026.

Third quarter 2026 highlights

• Revenue increased 8% to $2.17 billion; organic revenue was +7% and acquisition contribution was +1%
• GAAP net earnings increased 22% to $485 million; adjusted net earnings increased 5% to $586 million
• Adjusted EBITDA increased 7% to $864 million
• GAAP DEPS increased 33% to $4.88; adjusted DEPS increased 15% to $5.89

“Roper delivered another solid quarter, with 8% total revenue growth, 7% organic revenue growth, 7% EBITDA growth, and 15% adjusted DEPS growth. During the quarter, we deployed $436 million toward three bolt-on acquisitions for our iPipeline, Procare, and Strata businesses, and we received $1.2 billion in proceeds from Indicor’s sale of its instrumentation businesses,” said Neil Hunn, Roper Technologies’ President and CEO.

“This quarter, our businesses again brought several AI launches to market, highlighted by PowerPlan, Strata, and Vertafore. We are embedding agentic solutions directly into the workflows our customers rely on every day, and we are also evolving how we build, with smaller teams closer to customers and increasingly agentic development processes. Given the depth of our customer relationships, our proprietary and unique data sets, and our embedded position inside mission-critical workflows, we are well positioned to create value for customers with AI. We are laser focused on scaling adoption while continuing to accelerate innovation.”

“Driven by third quarter adjusted DEPS that exceeded our expectations, we are raising our full year adjusted DEPS guidance. With more than $6 billion of capital deployment capacity, we will continue allocating capital with discipline to drive free cash flow per share compounding for our shareholders,” concluded Mr. Hunn.

Increasing 2026 guidance

Roper now expects full year 2026 adjusted DEPS of $22.35 – $22.40, compared to previous guidance of $22.15 – $22.30.

For the fourth quarter of 2026, the Company expects adjusted DEPS of $5.95 – $6.00.

The Company’s guidance excludes the impact of unannounced future acquisitions or divestitures, proceeds from Indicor’s pending divestiture of its Cornell Pump and Roper Pump businesses, as well as potential share repurchases.

Conference call to be held at 8:00 AM (ET) today

A conference call to discuss these results has been scheduled for 8:00 AM ET on Thursday, October 22, 2026. The call can be accessed via webcast or by dialing +1 800-836-8184 (US/Canada) or +1 646-357-8785, using conference call ID 80101. Webcast information and conference call materials will be made available in the Investors section of Roper’s website (www.ropertech.com) prior to the start of the call. The webcast can also be accessed directly by using the following URL https://event.webcast. Telephonic replays will be available for up to two weeks and can be accessed by dialing +1 646-517-4150 with access code 80101 #.

Use of non-GAAP financial information

The Company supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non-GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial schedules or tables. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated.

Minority interest

Following the sale of a majority stake in its industrial businesses to CD&R, Roper holds a minority interest in Indicor. The fair value of Roper’s equity investment in Indicor is updated on a quarterly basis and reported as “equity investment (gain) loss, net.” Roper makes non-GAAP adjustments for the impacts associated with this investment.

Table 1: Revenue and adjusted EBITDA reconciliation ($M)
	Q3 2025				Q3 2026				V %
GAAP revenue	$	2,017			$	2,172			8	%
Components of revenue growth
Organic									7	%
Acquisitions									1	%
Foreign exchange									—	%
Total revenue growth									8	%
Adjusted EBITDA reconciliation
GAAP net earnings	$	398			$	485
Taxes		100				87
Interest expense		90				107
Depreciation		10				10
Amortization		221				225
EBITDA	$	819			$	914			12	%
Transaction-related expenses for completed acquisitions		4				6
Financial impacts associated with minority investments		(13	)			(56	)	A
Adjusted EBITDA	$	810			$	864			7	%
Adjusted EBITDA margin		40.2	%			39.8	%		(40 bps)

Table 2: Adjusted net earnings reconciliation ($M)
	Q3 2025				Q3 2026				V %
GAAP net earnings	$	398			$	485			22	%
Transaction-related expenses for completed acquisitions		3				5
Financial impacts associated with minority investments		(10	)			(71	)	A
Amortization of acquisition-related intangible assets		165				167		B
Adjusted net earnings C	$	557			$	586			5	%

Table 3: Adjusted DEPS reconciliation
	Q3 2025				Q3 2026				V %
GAAP DEPS	$	3.68			$	4.88			33	%
Transaction-related expenses for completed acquisitions		0.03				0.05
Financial impacts associated with minority investments		(0.09	)			(0.71	)	A
Amortization of acquisition-related intangible assets		1.53				1.68		B
Adjusted DEPS C	$	5.14			$	5.89			15	%

Table 4: Forecasted adjusted DEPS reconciliation
	Q4 2026						FY 2026 D
	Low end			High end			Low end				High end
GAAP DEPS E	$	4.27		$	4.32		$	25.60			$	25.65
YTD transaction-related expenses for completed acquisitions		—			—			0.05				0.05
YTD financial impacts associated with the minority investment in Indicor A	TBD			TBD				(9.86	)			(9.86	)
Amortization of acquisition-related intangible assets B		1.68			1.68			6.56				6.56
Adjusted DEPS C	$	5.95		$	6.00		$	22.35			$	22.40

Footnotes:

A.	Adjustments related to the financial impacts associated with the minority investment in Indicor as shown below ($M, except per share data). Forecasted results do not include any future impacts associated with our minority investment in Indicor, as these future impacts cannot be reasonably predicted. These impacts will be excluded from all non-GAAP results in future periods.
		Q3 2026A						Q4 2026E			FY 2026E			YTD 2026
	Pretax	$	(56	)				TBD			TBD			$	(1,059	)
	After-tax	$	(71	)				TBD			TBD			$	(996	)
	Per share	$	(0.71	)				TBD			TBD			$	(9.86	)
B.	Actual results and forecast of estimated amortization of acquisition-related intangible assets as shown below ($M, except per share data).
		Q3 2026A						Q4 2026E			FY 2026E
	Pretax	$	212				$	212		$	839
	After-tax	$	167				$	168		$	663
	Per share	$	1.68				$	1.68		$	6.56
C.	All actual and forecasted non-GAAP adjustments are taxed at 21% with the exception of the financial impacts associated with minority investments.
D.	Full-year 2026 DEPS guidance will not equal the sum of the quarters due primarily to the impact of share repurchases on quarterly versus full-year weighted-average diluted shares outstanding.
E.	Forecasted GAAP DEPS do not include any future impacts associated with our minority investment in Indicor. These impacts will be excluded from all non-GAAP results in future periods.

Note: Numbers may not foot due to rounding.

About Roper Technologies

Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.

Contact information:
Investor Relations
941-556-2601
investor-relations@ropertech.com

The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as “anticipate,” “estimate,” “plans,” “expects,” “projects,” “should,” “will,” “believes,” “intends” and similar words and phrases. These statements reflect management’s current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto, and our ability to develop, deploy, and use artificial intelligence in our platforms and offerings. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and volatile interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

Roper Technologies, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(Amounts in millions)
	September 30, 2026				December 31, 2025
ASSETS:
Cash and cash equivalents	$	311.0			$	297.4
Accounts receivable, net		981.1				1,001.0
Inventories, net		153.3				141.7
Income taxes receivable		56.7				128.2
Unbilled receivables		152.6				124.0
Prepaid expenses and other current assets		291.6				235.8
Total current assets		1,946.3				1,928.1
Property, plant and equipment, net		158.4				156.9
Goodwill		21,555.0				21,341.2
Other intangible assets, net		9,455.7				9,764.2
Deferred taxes		69.0				73.3
Equity investment		577.0				796.3
Other assets		576.9				517.0
Total assets	$	34,338.3			$	34,577.0
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Accounts payable	$	176.3			$	150.3
Accrued compensation		288.9				293.0
Deferred revenue		1,889.3				1,906.8
Other accrued liabilities		590.1				642.3
Income taxes payable		211.5				28.0
Current portion of long-term debt, net		1,415.1				705.2
Total current liabilities		4,571.2				3,725.6
Long-term debt, net of current portion		8,304.6				8,595.8
Deferred taxes		1,785.2				1,883.1
Other liabilities		504.7				491.0
Total liabilities		15,165.7				14,695.5
Common stock, 350.0 shares authorized; 109.5 shares issued and 99.0 outstanding at September 30, 2026 and 109.3 shares issued and 106.6 outstanding at December 31, 2025		1.1				1.1
Additional paid-in capital		3,473.3				3,292.2
Retained earnings		19,091.2				17,205.7
Accumulated other comprehensive loss		(138.2	)			(101.4	)
Treasury stock, 10.5 shares at September 30, 2026 and 2.7 shares at December 31, 2025		(3,254.8	)			(516.1	)
Total stockholders’ equity		19,172.6				19,881.5
Total liabilities and stockholders’ equity	$	34,338.3			$	34,577.0

Roper Technologies, Inc.
Condensed Consolidated Statements of Earnings (unaudited)
(Amounts in millions, except per share data)
	Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
Net revenues	$	2,171.8			$	2,017.5			$	6,376.0			$	5,843.9
Cost of sales		649.2				614.5				1,929.4				1,801.8
Gross profit		1,522.6				1,403.0				4,446.6				4,042.1
Selling, general and administrative expenses		899.4				830.0				2,669.1				2,395.0
Income from operations		623.2				573.0				1,777.5				1,647.1
Interest expense, net		106.7				89.7				317.4				231.7
Equity investment (gain) loss, net		(56.2	)			(12.9	)			(1,058.7	)			14.9
Other (income) expense, net		0.6				(2.0	)			3.7				(1.0	)
Earnings before income taxes		572.1				498.2				2,515.1				1,401.5
Income taxes		87.4				99.7				353.0				293.6
Net earnings	$	484.7			$	398.5			$	2,162.1			$	1,107.9
Net earnings per share:
Basic	$	4.90			$	3.70			$	21.36			$	10.31
Diluted	$	4.88			$	3.68			$	21.30			$	10.23
Weighted average common shares outstanding:
Basic		98.9				107.6				101.2				107.5
Diluted		99.4				108.4				101.5				108.3

Roper Technologies, Inc.
Selected Segment Financial Data (unaudited)
(Amounts in millions; percentages of net revenues)
	Three months ended September 30,												Nine months ended September 30,
		2026						2025						2026						2025
	Amount			%			Amount			%			Amount			%			Amount			%
Net revenues:
Application Software	$	1,239.7					$	1,161.0					$	3,612.0					$	3,324.1
Network Software		446.1						413.4						1,304.6						1,174.7
Technology Enabled Products		486.0						443.1						1,459.4						1,345.1
Total	$	2,171.8					$	2,017.5					$	6,376.0					$	5,843.9
Gross profit:
Application Software	$	865.5		69.8	%		$	801.0		69.0	%		$	2,511.8		69.5	%		$	2,275.1		68.4	%
Network Software		378.0		84.7	%			346.9		83.9	%			1,101.8		84.5	%			983.3		83.7	%
Technology Enabled Products		279.1		57.4	%			255.1		57.6	%			833.0		57.1	%			783.7		58.3	%
Total	$	1,522.6		70.1	%		$	1,403.0		69.5	%		$	4,446.6		69.7	%		$	4,042.1		69.2	%
Operating profit*:
Application Software	$	357.6		28.8	%		$	323.0		27.8	%		$	1,000.8		27.7	%		$	894.4		26.9	%
Network Software		189.6		42.5	%			178.1		43.1	%			540.0		41.4	%			514.1		43.8	%
Technology Enabled Products		160.7		33.1	%			150.2		33.9	%			480.8		32.9	%			467.9		34.8	%
Total	$	707.9		32.6	%		$	651.3		32.3	%		$	2,021.6		31.7	%		$	1,876.4		32.1	%
* Segment operating profit is before unallocated corporate general and administrative expenses and enterprise-wide stock-based compensation. These expenses were $84.7 and $78.3 for the three months ended September 30, 2026 and 2025, respectively, and $244.1 and $229.3 for the nine months ended September 30, 2026 and 2025, respectively.

Roper Technologies, Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(Amounts in millions)
	Nine months ended September 30,
		2026				2025
Cash flows from operating activities:
Net earnings	$	2,162.1			$	1,107.9
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property, plant and equipment		30.4				29.9
Amortization of intangible assets		666.3				638.0
Amortization of deferred financing costs		9.3				8.6
Non-cash stock compensation		163.9				128.7
Equity investment (gain) loss, net		(1,058.7	)			14.9
Income tax provision		353.0				293.6
Changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable		22.9				(0.5	)
Unbilled receivables		(28.2	)			(7.2	)
Inventories		(12.6	)			(18.2	)
Prepaid expenses and other current assets		(48.7	)			(27.9	)
Accounts payable		26.2				13.2
Other accrued liabilities		(57.2	)			(48.9	)
Deferred revenue		(36.9	)			28.5
Cash taxes paid for gain on disposal of equity investment		—				(30.2	)
Cash income taxes paid, excluding tax associated with gain on disposal of equity investment		(283.7	)			(307.6	)
Other, net		(25.9	)			(20.5	)
Cash provided by operating activities		1,882.2				1,802.3
Cash flows from (used in) investing activities:
Acquisitions of businesses, net of cash acquired		(463.2	)			(3,280.4	)
Capital expenditures		(35.4	)			(37.6	)
Capitalized software expenditures		(46.8	)			(42.8	)
Distributions from equity investment		6.7				5.1
Proceeds from Indicor transaction		1,239.2				—
Cash receipts on beneficial interest in sold receivables		15.2				—
Other, net		0.3				1.7
Cash provided by (used in) investing activities		716.0				(3,354.0	)
Cash flows from (used in) financing activities:
Proceeds from senior notes		—				2,000.0
Payments of senior notes		—				(700.0	)
Borrowings under revolving credit facility, net		400.0				585.0
Debt issuance costs		(3.9	)			(19.5	)
Cash dividends to stockholders		(281.4	)			(266.0	)
Repurchases of common stock		(2,726.7	)			—
Proceeds from stock-based compensation, net		19.3				79.4
Treasury stock sales under employee stock purchase plan		12.7				17.4
Other, net		9.1				(42.0	)
Cash provided by (used in) financing activities		(2,570.9	)			1,654.3
Effect of exchange rate changes on cash		(13.7	)			29.2
Net increase in cash and cash equivalents		13.6				131.8
Cash and cash equivalents, beginning of period		297.4				188.2
Cash and cash equivalents, end of period	$	311.0			$	320.0

The renewal will support more personalized and rewarding experiences for Sephora customers and Beauty Insider members

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial^® (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, today announced a long-term renewal of its credit and loyalty program agreement with Sephora, one of the world’s leading prestige beauty retailers.

The renewal agreement reflects a shared commitment to delivering value for Sephora customers. Building on years of strong collaboration, Bread Financial and Sephora will continue to deepen the connection between Sephora’s branded credit and its Beauty Insider loyalty program, creating more personalized, synergistic and rewarding experiences across the customer journey.

“Sephora is a meaningful partner for Bread Financial, and this renewal reflects the deeply integrated partnership that has shaped our work together,” said Dennis McCarthy, executive vice president and chief revenue officer, Bread Financial. “Through our combined credit and signature loyalty programs, we are excited to play a role in enabling Sephora customers to be inspired by their unique beauty. We’re proud to work alongside Sephora to deliver experiences that feel personalized and rewarding in any channel customers choose to shop. We look forward to continuing to help Sephora enhance customer engagement and bring even greater value to Beauty Insider members.”

Under terms of the renewal agreement, Bread Financial and Sephora will continue advancing Sephora’s credit and loyalty offerings through enhanced personalization, innovative marketing strategies and seamless experiences across channels. Supported by ongoing investments in analytics, digital capabilities and customer insights, the program will deliver more relevant and rewarding experiences that deepen engagement with Beauty Insider members, strengthen brand affinity and support Sephora’s commitment to exceeding evolving customer expectations.

“At Sephora, we’re constantly looking for ways to deepen our relationships with our community and elevate the value of being a Beauty Insider member,” said Emeline Berlind, Senior Vice President, GM, Loyalty at Sephora. “Our longstanding partnership with Bread Financial has enabled us to build on the strong foundation and continue to create rewarding, personalized experiences for our clients. We’re excited to keep innovating alongside a partner who shares our commitment to putting customers first, and we look forward to shaping what’s next for the loyalty and credit experiences our community values most.”

About Bread Financial^®
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, health & beauty, technology, electronics, jewelry, home and specialty apparel through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

About Sephora
Sephora is the world’s leading global prestige beauty retail brand. With 55,000 passionate employees operating in 37 markets, Sephora connects customers and beauty brands within the world’s most trusted and dynamic beauty community. We serve a highly engaged community of hundreds of millions of beauty followers across our global omnichannel network of more than 3,400 stores and iconic flagships, and our e-commerce and digital platforms, offering personalized and immersive seamless experiences across every touchpoint. With our curation of close to 500 brands and our own label, Sephora Collection, we offer the most unique and diverse range of prestige beauty products, tailored to our customers’ needs from fragrance to make-up, haircare, skincare and beyond, as we constantly reimagine the world of prestige beauty.

Since our inception in 1969 in Limoges, France, and as part of the LVMH Group since 1997, we have been disrupting the prestige beauty retail industry. Today, we continue to break with convention to drive our mission: champion a world of inspiration and inclusion where everyone can celebrate their beauty.

Contacts 
Brian Vereb — Investor Relations 
Brian.Vereb@breadfinancial.com

Susan Haugen — Investor Relations 
Susan.Haugen@breadfinancial.com 

Rachel Stultz — Media 
Rachel.Stultz@breadfinancial.com 

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial^® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced its third quarter 2026 financial results. All earnings-related materials are now available at the company’s investor relations website, here. 

Bread Financial President and Chief Executive Officer Ralph Andretta and Chief Financial Officer Perry Beberman will host a conference call at 8:30 a.m. ET today to discuss results. A link to the conference call will be available at the company’s investor relations website, and a replay will also be available there following the call. 

About Bread Financial^® 
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, health & beauty, technology, electronics, jewelry, home and specialty apparel through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn. 

Contacts 
Brian Vereb — Investor Relations 
Brian.Vereb@breadfinancial.com 

Susan Haugen — Investor Relations 
Susan.Haugen@breadfinancial.com 

Rachel Stultz — Media 
Rachel.Stultz@breadfinancial.com 

ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Wisconsin-based transportation and logistics provider WEL Companies is using Descartes’ broker transportation management system (TMS) integrated with CARRIER1 Vault to move customers’ goods using its own trucks and to arrange shipments with other trucking companies in its for-hire network. The combined solution helps WEL’s freight brokers manage the shipment lifecycle with the Descartes solution while exchanging load information, status updates and delivery documents with the carriers and drivers moving the freight.

“The Descartes and CARRIER1 collaboration lets WEL automate communication and shipment data across our brokerage, our assets, and our for-hire carrier network, without our brokers ever leaving their TMS,” said Eric Lenze, EVP at WEL Companies. “That means a faster shipment lifecycle and a better experience for our customers.”

Descartes’ cloud-based broker TMS helps freight brokers and third-party logistics providers manage order entry, load coverage, carrier acceptance, dispatching and carrier communications. CARRIER1 Vault extends these workflows to trusted carriers and drivers through digital tendering, shipment tracking, communication and document exchange. As a load moves, carrier assignments, driver and equipment details, status updates and documents such as rate confirmations, bills of lading and proof of delivery can flow back to the corresponding load in the Descartes solution. The integration also supports carrier, driver and equipment verification, helping brokers reduce manual data entry and the need to piece together information from emails, spreadsheets and phone calls.

“Brokers need the systems that they already use to do more for them,” said Travis Rhyan, CEO of CARRIER1. “Connecting Vault with Descartes’ TMS brings the broker, carrier and driver into the same flow of information. The broker stays in their Descartes solution, the carrier gets what they need to move the load, and the information comes back without someone having to chase it down manually.”

“We’re pleased to help WEL Companies simplify brokerage operations by connecting more of the shipment lifecycle back into Descartes’ TMS through our integrated solution,” said Andrew Wimer, Associate General Manager at Descartes. “Our integration strategy gives brokers access to specialized capabilities while keeping Descartes’ TMS at the center of their operations. By collaborating with CARRIER1, we’re extending that approach to the carriers and drivers moving the freight, so brokers can spend less time gathering updates and documents and more time managing exceptions and serving customers.”

Learn more about Descartes’ transportation management solutions.

About WEL Companies

WEL Companies is a family-owned transportation, logistics and warehousing company headquartered in De Pere, Wisconsin. Founded in 1975, WEL provides refrigerated truckload and less-than-truckload transportation, integrated logistics and warehousing services. Learn more at www.welcompanies.com.

About CARRIER1

CARRIER1 connects freight brokers, carriers and drivers through technology designed to simplify the work surrounding a load. Its Vault platform integrates with existing transportation management systems to support carrier engagement, verification, shipment execution and document exchange. Learn more at www.carrier1.com.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack                                                                     
Tel: 226-750-8050                                 
cstrohack@descartes.com  

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ transportation management solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

• BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancer
• The global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer
• This will be the first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy^®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (“BMS”).

ROSETTA Breast-01 is a global, double-blinded Phase 3 clinical trial (NCT07173751) currently evaluating pumitamig in combination with chemotherapy versus chemotherapy in patients with locally advanced or metastatic PD-L1 low or negative TNBC (CPS < 10), initiated based on positive results from a global Phase 2 trial. In line with the evolving treatment landscape in this indication, BioNTech and BMS plan to adapt ROSETTA Breast-01 replacing chemotherapy with sacituzumab govitecan, pending regulatory authority approval, to ensure that patients are receiving the latest standard of care treatment.

Under the terms of the agreement, BioNTech will continue to sponsor and lead the ROSETTA Breast-01 trial. Gilead will supply sacituzumab govitecan for the combination trial.

“When the ROSETTA Breast-01 trial was initiated, chemotherapy was the only option for patients with PD‑L1 negative advanced TNBC. While chemotherapy remains a standard first-line option, TROP2-directed ADCs like sacituzumab govitecan are quickly becoming the new global standard of care. I am excited to evaluate the combination of pumitamig and sacituzumab govitecan in the ROSETTA Breast-01 trial to potentially further amplify the already meaningful improvement in patient outcomes that sacituzumab govitecan has demonstrated over chemotherapy,” said Peter Schmid, M.D., Ph.D., Lead Investigator and Director of the Breast Cancer Centre at St. Bartholomew’s Hospital.

Pumitamig is currently being investigated in seven ongoing global Phase 3 trials and 10+ Phase 2 novel-novel combination trials. ROSETTA Breast-01 will be the first global Phase 3 trial of pumitamig in combination with an ADC. BioNTech and Bristol Myers Squibb plan to evaluate the full potential of pumitamig in additional Phase 3 novel combination trials in multiple solid tumors, leveraging their broad oncology pipelines and exploring other potential additional collaborations.

“We aim to maximize potential benefit for patients with triple-negative breast cancer. Adapting ROSETTA Breast-01 to reflect the evolving standard of care gives the trial the best chance to inform clinical practice and, ultimately, treatment decisions for patients,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “Combining pumitamig as a potential backbone with complementary modalities such as ADCs is central to our therapeutic approach. Sacituzumab govitecan has advanced first‑line treatment of triple-negative breast cancer. By combining pumitamig and sacituzumab govitecan, we aim to determine whether this approach can further improve outcomes of patients.”

The use of pumitamig and sacituzumab govitecan in patients with first-line PD-L1 negative metastatic TNBC is investigational, and the safety and efficacy of this combination has not been established.

About Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which is defined by a lack of hormone receptors (estrogen or progesterone) and HER2 protein, accounts for about 10-15% of all invasive breast cancer cases.¹ It is an aggressive type of breast cancer that tends to grow and spread faster and has a worse prognosis compared to other breast cancer types. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. The 5-year survival rate for patients with metastatic TNBC is only 15%, emphasizing the need for new treatment options.¹

About Pumitamig
Pumitamig is an investigational bispecific immunomodulator, jointly developed by BioNTech and BMS, designed to cooperatively bind to PD-L1 and VEGF-A. It is aimed at restoring the immune system’s ability to recognize and destroy tumor cells while simultaneously cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), preventing them from growing and proliferating. By anchoring to PD-L1 receptors on tumor cells, we believe pumitamig localizes VEGF-A blockade within the tumor microenvironment, potentially enhancing antitumor activity while minimizing systemic exposure.

More than 4,000 patients have been treated with pumitamig in clinical trials to date. Seven global Phase 3 trials with registrational potential are currently ongoing, evaluating pumitamig plus chemotherapy compared to standard of care treatments, in first-line small cell lung cancer (ROSETTA Lung-01, NCT06712355); first-line non-small cell lung cancer (ROSETTA Lung-02, NCT06712316); unresectable stage III non-small cell lung cancer (ROSETTA Lung-201, NCT07361497); first-line advanced PD-L1 ≥ 50% non-small cell lung cancer (ROSETTA Lung-202, NCT07361510); first-line triple-negative breast cancer (ROSETTA Breast-01, NCT07173751); first-line microsatellite stable colorectal cancer (ROSETTA CRC-203, NCT07221357); and first-line gastric cancer (ROSETTA Gastric-204, NCT07221149). Pumitamig is also being explored in 10+ novel-novel combination trials with ADCs and other novel modalities, with the aim of expanding its role across tumor types and identifying additional pivotal opportunities.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s collaboration with Bristol Myers Squibb (BMS); BioNTech’s collaboration with Gilead; BioNTech and BMS’s ability to successfully co-develop and co-commercialize pumitamig (also known as BNT327 or BMS986545), if approved; the rate and degree of market acceptance of pumitamig, if approved; the initiation, timing, progress, and results of BioNTech’s research and development programs, including BioNTech’s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential indications in which pumitamig may be approved, if at all; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s product candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

BioNTech
Media Relations
Jasmina Alatovic
Media@biontech.de

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

1 American Cancer Society. Triple-Negative Breast Cancer. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html. Accessed October 15, 2026.

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, today announced that its Board of Directors declared quarterly dividends on its preferred stock and an increased quarterly dividend on its common stock for the fourth quarter of 2026.

On the Company’s 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (NYSE: BFH-PrA), the Board of Directors declared a quarterly cash dividend of $21.56 per share (equivalent to $0.539 per depositary share, each representing a 1/40th interest in a share of preferred stock). The dividend is payable on December 15, 2026 to preferred stockholders of record at the close of business on November 30, 2026.

On the Company’s 8.875% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (NYSE: BFH-PrB), the Board of Directors declared a quarterly cash dividend of $22.19 per share (equivalent to $0.55475 per depositary share, each representing a 1/40th interest in a share of preferred stock). The dividend is payable on December 15, 2026 to preferred stockholders of record at the close of business on November 30, 2026.

On the Company’s common stock, the Board of Directors declared a quarterly cash dividend of $0.25 per share, a 9% increase from the prior quarterly dividend of $0.23 per share, payable on December 15, 2026 to common stockholders of record at the close of business on November 30, 2026.

About Bread Financial^®
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, specialty apparel, health & beauty, jewelry, sporting goods, technology and electronics, as well as home & furniture through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.​

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Contacts
Brian Vereb – Investor Relations
Brian.Vereb@BreadFinancial.com

Susan Haugen – Investor Relations
Susan.Haugen@BreadFinancial.com

Rachel Stultz – Media
Rachel.Stultz@BreadFinancial.com

COSTA MESA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today announced that it plans to release the Company’s 2026 third quarter financial results on November 5, 2026, prior to the stock market opening. Stephen G. Oswald, the Company’s chairman, president and chief executive officer, and Suman Mookerji, the Company’s senior vice president and chief financial officer, will host a call that day at 10:00 a.m. PT (1:00 p.m. ET) to review these results.

To access the conference call, please pre-register using this registration link. Registrants will receive a confirmation with dial-in details. Mr. Oswald and Mr. Mookerji will speak on behalf of the Company and anticipate the meeting and Q&A period to last approximately 45 minutes. A live webcast of the event can be accessed using this link. A replay of the webcast will be available on the Ducommun website at www.ducommun.com.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added innovative products, aftermarket and manufacturing solutions to customers in the aerospace, defense and space markets and aspires to contribute to the advancement of those industries. Founded in 1849, the Company specializes in two core areas — Electronic Systems and Structural Systems — to produce complex products and components for commercial aircraft platforms and mission-critical military and space programs. For more information, visit Ducommun.com.

CONTACTS:

Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665

ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its third quarter results before the market open on Thursday, November 12, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day.

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13762373. The replay will be available until November 19, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available for one week following the call.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 39 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.

CONTACT: Investor Contact

Matt Buckhalter
Chief Financial Officer
Ir@aveanna.com

Built on data, analytics, specialized knowledge and AI-powered capabilities, Brown & Brown COMPASS helps customers and teammates make more informed decisions.

DAYTONA BEACH, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE: BRO) (“the Company”) today introduced COMPASS, a connected intelligence ecosystem that brings together the Company’s data, analytics, specialized knowledge and AI-enabled capabilities to help customers better understand risk and make more informed insurance decisions.

Built specifically to enhance insurance strategy and portfolio optimization, Brown & Brown COMPASS brings together proprietary data, advanced analytics, specialized knowledge, and AI-powered capabilities. While many AI solutions in the market adapt a general-purpose model to a single workflow, COMPASS was built around the data, decisions and experience that drive the insurance business.

“Insurance organizations have access to more data and technology than ever before, but the industry’s greatest opportunity is to connect those capabilities around the decisions customers and insurance professionals make every day,” said Steve Hearn, president of Brown & Brown Retail. “COMPASS brings together capabilities that have traditionally operated separately, giving our teams a more complete view of a customer’s risks and opportunities and helping turn fragmented information into relevant insight. That broader context can support more informed recommendations, better decisions and stronger outcomes across the insurance value chain.”

The impact is already evident. In Employee Benefits, customers using Brown & Brown’s Health Plan Intelligence (HPI) capabilities have experienced an average five-year cost trend of less than 4%, compared with an industry and market norm of approximately 7% to 9%.

In Property & Casualty, COMPASS analytics helped a Fortune 50 company evaluate whether its insurance purchasing philosophy aligned with its appetite for hazard risk. The analysis informed a significant restructuring of the company’s insurance program, reducing premium spending by 65% while also substantially reducing potential risk volatility.

Brown & Brown COMPASS will also support digital quoting and servicing experiences that simplify how Personal Lines customers evaluate and manage coverage. For ultra-high-net-worth and single-family-office customers, it will deliver institutional-grade analytics to maximize buying power, evaluate risk transfer and optimize portfolios, capabilities rarely available in Personal Lines.

“One of our greatest strengths is the knowledge we’ve built across Brown & Brown over many years,” said Powell Brown, president and chief executive officer. “COMPASS helps connect that knowledge in new ways, making it easier for our teammates to turn insights into action for our customers. When we help our customers make more informed decisions, everybody wins.”

COMPASS builds on the Company’s broader investment in data, analytics and AI, including the creation of its Digital Innovation and Insights Group and collaborations with Anthropic, McKinsey and Accenture.

“The innovation behind COMPASS is not one technology or tool, but the way we are bringing together Brown & Brown’s data, analytics, specialized knowledge and AI-enabled capabilities in a connected ecosystem,” said Arun Narayanan, chief innovation officer at Brown & Brown. “By building around the real-world decisions our teammates and customers make, we can develop solutions that are both practical and scalable, accelerate how insight is applied across our business and continually expand what COMPASS can deliver.”

By the end of 2026, the Company expects COMPASS-powered knowledge assistants and business intelligence solutions to be available to thousands of teammates, beginning in the U.S. and expanding to additional markets over time. An expanded suite of customer solutions across Property & Casualty, Employee Benefits and Personal Lines is planned for early 2027.

To learn more about COMPASS, visit https://us.bbrown.com/compass.

About Brown & Brown, Inc.
Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

This press release may contain certain forward-looking statements relating to future results. These statements are not historical facts but instead represent only Brown & Brown’s current belief regarding future events, many of which, by their nature, are inherently uncertain and outside of Brown & Brown’s control. It is possible that Brown & Brown’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning Brown & Brown and its business, including factors that potentially could materially affect Brown & Brown’s financial results and condition, as well as its other achievements, is contained in Brown & Brown’s filings with the Securities and Exchange Commission. All forward-looking statements made herein are made only as of the date of this release, and Brown & Brown does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which Brown & Brown hereafter becomes aware.

For more information:
Jenny Goco
Vice President of Public Relations & Communications
(386) 333-6066
jenny.goco@bbrown.com

To Nasdaq Copenhagen

 22 October 2026

FIXING OF COUPON RATES       

Fixing of coupon rates effective from 26 October 2026

Effective from 26 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 26 October 2026 to 25 January 2027:

Uncapped bonds
DK0030522818, (SNP), maturity in 2027, new rate as at 26 October 2026: 3.2770% pa

Effective from 26 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 26 October 2026 to 26 January 2027:

Uncapped bonds
DK0030513585, (Tier2), maturity in 2032, new rate as at 26 October 2026: 6.4900% pa

Questions may be directed to Investor Relations at investor_relations@nykredit.dk or Press Officer Peter Klaaborg, tel +45 44 55 14 94.

Attachment

• Fixing of coupon rates – Nykredit Realkredit – 20261022